Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Shares of Life Insurance Corporation of India (LIC) are banned from F&O trading on 6 August 2026.
New listing:
MV Electrosystems will make its stock market debut today. The Rs 290-crore IPO was offered in a price band of Rs 400–425 per share. The issue received bids for 75.30 crore shares against 39.87 lakh shares on offer, resulting in an overall subscription of 188.85 times.
Juniper Green Energy is also set to debut on the bourses today. The company's Rs 1,800-crore IPO, priced in the Rs 214–225 per share band, received bids for 46.96 crore shares against 5.89 crore shares on offer, translating into an overall subscription of 7.97 times.
Earnings Today:
Life Insurance Corporation of India (LIC), Hero MotoCorp, Britannia Industries, Lupin, Samvardhana Motherson International, Apollo Tyres, Blue Star, Fortis Healthcare, Crompton Greaves Consumer Electricals, Bosch Home Comfort India, Premier Energies, NCC, Emcure Pharmaceuticals, EIH, Aegis Logistics, PG Electroplast, Firstsource Solutions, Signatureglobal (India), RateGain Travel Technologies, Campus Activewear will declare their quarterly results later today.
Stocks to Watch:
Aurobindo Pharma reported 28.11% jump in consolidated net profit to Rs 1,056.56 crore in Q1 FY27 compared with Rs 824.75 crore in Q1 FY26. Revenue from operations climbed 16.30% YoY to Rs 9,150.35 crore in Q1 FY27.
PB Fintech (Policy Bazaar)’s consolidated net profit jumped 92.54% to Rs 162.89 crore on 40.08% increase in revenue from operations to Rs 1,888.28 crore in Q1 FY27 over Q1 FY26.
Biocon’s consolidated net profit surged 872.27% to Rs 142.35 crore in Q1 FY27, compared with Rs 36.76 crore in Q1 FY26. Net sales jumped 10% YoY to Rs 4,336 crore in Q1 FY27.
Neuland Laboratories reported 962.37% surge in consolidated net profit to Rs 147.67 crore in Q1 FY27 compared with Rs 13.9 crore posted in year-ago period. Net sales soared 119.16% YoY to Rs 641.58 crore in the quarter ended 30th Jun 2026.
Bikaji Foods International's consolidated net profit edged up 0.4% YoY to Rs 60.14 crore in Q1 FY27, compared with Rs 59.90 crore a year ago. Net sales grew 12.5% YoY to Rs 734.26 crore.
JK Lakshmi Cement reported 29.60% decline in standalone net profit to Rs 106.77 crore in Q1 FY27 from Rs 151.67 crore in Q1 FY26. Net sales rose 9.41% YoY to Rs 1,904.78 crore in Q1 FY27.
The scope of the inspection included four biosimilar products and assessed the mammalian and microbial drug substance manufacturing facility, prefillable syringe and vial filling facility, packaging and labelling operations, as well as quality control testing and release laboratories.
The company said CuraTeQ's drug substance and drug product GMP facility is already certified by the European Medicines Agency (EMA) and the World Health Organization (WHO). The ANVISA approval further strengthens the company's regulatory credentials and enhances its ability to supply biosimilar products to Brazil and the broader Latin American market.
Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services.
The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.
The counter slipped 2.65% to Rs 1,538.60 on the BSE.
The object of incorporation of this wholly owned step down subsidiary is to undertake manufacturing operations in Indonesia.
Aurobindo Pharma USA Inc., (APUSA), a wholly owned subsidiary of Aurobindo Pharma, announced the successful completion of its acquisition of Lannett Company, Inc., USA (Lannett), from Lannett Seller Holdco, Inc., following receipt of approval from the U.S. Federal Trade Commission on 18 June 2026.
Effective 29 June 2026, Lannett has become a wholly owned subsidiary of APUSA and will operate as Lannett Company LLC.
The integration process will commence immediately, with a strong emphasis on ensuring uninterrupted access to critical medications, maintaining trusted relationships with partners, and supporting employees throughout the transition.
The inspection concluded with two observations. The company said it will respond to the observations within the stipulated timeline.
Aurobindo Pharma reiterated its commitment to maintaining the highest quality manufacturing standards and said it will keep the stock exchanges informed of any further developments related to the inspection.
The official announcement was made on Saturday, 27 June 2026.
Aurobindo Pharma is engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services. The company reported a 2% rise in consolidated net profit to Rs 921.26 crore on a 4.4% increase in net sales to Rs 8,751.50 crore in Q4 FY26 over Q4 FY25.
The counter advanced 1.15% to Rs 1,572.85 on the BSE.
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Auroactive Pharma (a wholly owned subsidiary of the Company), which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh, from 22 June 2026, to 26 June 2026.
The inspection concluded with 2 observations and will be responded to within the stipulated time.